TP53 and triple-negative breast carcinoma: The tumour suppressor TP53 is highly mutated in cancer [1], however, in breast cancer, TP53 mutation status is highly variable, ranging from approximately 10% in Luminal A patients to 80% in triple-negative breast cancers (TNBCs) [2].